Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

Market Cap	195.11B
Revenue (ttm)	72.27B
Net Income (ttm)	22.38B
Shares Out	886.45M
EPS (ttm)	25.24
PE Ratio	8.72
Forward PE	8.05
Dividend	11.00 (5.00%)
Ex-Dividend Date	Nov 24, 2024

Volume	280,271
Average Volume	379,053
Open	220.00
Previous Close	219.70
Day's Range	219.50 - 220.30
52-Week Range	197.20 - 249.80
Beta	0.14
RSI	63.73
Earnings Date	Apr 30, 2025

About DSE:SQURPHARMA

Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, anthelmintics, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, antioxid...

• Industry: Pharmaceutical Preparations
• Founded: 1958
• Employees: 12,453
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SQURPHARMA

Financial Performance

In 2024, DSE:SQURPHARMA's revenue was 70.10 billion, an increase of 15.47% compared to the previous year's 60.71 billion. Earnings were 20.93 billion, an increase of 10.25%.